Today is Rare Disease Day 2016. Because it is an important field for Biotech, we went back to review some of our best articles on the topic from the Labiotech archives.
Here are some of our best – in addition to an overview of 7 Rare diseases and who in Biotech is working on them.
We wanted to get a deeper understanding of what is today considered a Rare Disease, who is acting the field and the reasons for so many Biotech companies to dive into the field.
We had a chat with three key opinion leaders from Europe to get an expert view on the subject: Andrew Weiss, SVP Communication from Actelion, Karen Aiach, the Founder & CEO of Lysogene and Stephane Boissel, the CEO of TxCell.
We interviewed the Founder and CEO of Lysogene from Paris (France).